Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,460.43 -8.87 (-0.16%) Dow
38,947.94 -164.22 (-0.42%) Nasdaq
17,733.56 +15.90 (+0.09%) Bitcoin USD
61,784.55 +640.58 (+1.05%) CMC Crypto 200
1,277.67 -6.11 (-0.48%)
ITCI Jun 2024 75.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:48PM EDT. Market open.
| Previous close | 1.0000 |
| Open | 1.2000 |
| Bid | 0.6500 |
| Ask | 2.4500 |
| Strike | 75.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.0000 - 2.9300 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.7k |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.